Lausanne, Switzerland, May 17, 2021.

Rheon Medical SA, a Swiss medical device company active in the surgical treatment of glaucoma, announces that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to the eyeWatch technology, the world’s first adjustable glaucoma shunt for the treatment of refractory glaucoma. The eyeWatch technology has already received the CE-mark in 2019 and is currently marketed in European and Asian markets. The Company expects to initiate US-based clinical trials evaluating the therapy early 2022.

Download PDF